Viva Biotech and NVIDIA Advance AI-Driven Mini-Binder Design for Drug Discovery

Viva Biotech announced in a press release that it has optimized its Proteina-Complexa model using NVIDIA technology to enhance AI-driven drug discovery. The project focuses on designing mini-binders that target ActRIIA, a receptor associated with muscle wasting and lean mass imbalance.

The collaboration highlights Viva Biotech’s “Lab-in-the-Loop” workflow, integrating computational protein design with high-throughput protein production and biophysical evaluation. This approach combines in silico modeling with experimental validation to accelerate the identification of viable drug candidates.

By leveraging NVIDIA BioNeMo and its own AI-driven discovery platform, Viva Biotech improved the efficiency and specificity of mini-binder designs. The company reported that this AI-guided process reduced both the time and cost compared to traditional drug candidate development methods.

Viva Biotech stated that it will continue to strengthen its AI algorithm development and further apply its platform to accelerate drug discovery and development.